Clinical efficacy of porcine pulmonary surfactant combined with budesonide suspension intratracheal instillation in the treatment of neonatal meconium aspiration syndrome.
- Author:
Xiu-Zhen TAN
1
;
Shi-Guang WU
;
Jian-Hua ZHANG
;
Xiao-Fen LI
;
Ping-Ming GAO
;
Yu WANG
Author Information
- Publication Type:Journal Article
- MeSH: Animals; Budesonide; administration & dosage; Female; Humans; Infant, Newborn; Length of Stay; Male; Meconium Aspiration Syndrome; complications; drug therapy; Prospective Studies; Pulmonary Surfactants; administration & dosage; Suspensions; Swine; Trachea
- From: Chinese Journal of Contemporary Pediatrics 2016;18(12):1237-1241
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo study the clinical efficacy of porcine pulmonary surfactant (PS) combined with budesonide suspension intratracheal instillation in the treatment of neonatal meconium aspiration syndrome (MAS).
METHODSSeventy neonates with MAS were enrolled for a prospective study. The neonates were randomly assigned to PS alone treatment group and PS+budesonide treatment group (n=35 each). The PS alone treatment group was given PS (100 mg/kg) by intratracheal instillation. The treatment group was given budesonide suspension (0.25 mg/kg) combined with PS (100 mg/kg).
RESULTSThe rate of repeated use of PS in the PS+ budesonide group was significantly lower than that in the PS alone group 12 hours after treatment (p<0.05). The improvement of PaO/FiO, TcSaO, PaO, and PaCOin the PS+ budesonide group was significantly greater than that in the PS alone group 6, 12, and 24 hours after treatment (p<0.05). The chest X-ray examination showed that the pulmonary inflammation absorption in the PS+ budesonide group was significantly better than that in the PS alone group 48 hours after treatment (p<0.05). The incidence of complications in the PS+budesonide group was significantly lower than that in the PS alone group (p<0.05), and the average hospitalization duration was significantly shorter than that in the PS alone group (p<0.01).
CONCLUSIONSPS combined with budesonide suspension intratracheal instillation for the treatment of neonatal MAS is effective and superior to PS alone treatment.